Sobi Eyes International Expansion With Growing Late-Stage Pipeline
Revenues Grew By 8% In 2020
Sobi is extending its reach in international markets including Russia and China and expects its late-stage R&D pipeline to drive growth.
You may also be interested in...
Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.
Swedish Orphan Biovitrum has taken a stake in Selecta and got access to SEL-212, which it is hoping will win a head-to-head trial against Horizon's Krystexxa, the gold standard for chronic refractory gout.
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.